Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different health outcomes. The findings show benefits for brain and heart health, but ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

However, this popular class of drugs, which also includes Mounjaro and Zepbound, may cause health issues with the gastrointestinal system, kidneys, and pancreas. That’s the conclusion of a new ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...